FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:1464-1476 April 6, 2006 Number 14 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Gibbons, R. J. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background The combined use of anticoagulants, antiplatelet agents, and invasive coronary procedures reduces ischemic coronary events but also increases bleeding in patients with acute coronary syndromes. We therefore assessed whether fondaparinux would preserve the anti-ischemic benefits of enoxaparin while reducing bleeding.

Methods We randomly assigned 20,078 patients with acute coronary syndromes to receive either fondaparinux (2.5 mg daily) or enoxaparin (1 mg per kilogram of body weight twice daily) for a mean of six days and evaluated death, myocardial infarction, or refractory ischemia at nine days (the primary outcome); major bleeding; and their combination. Patients were followed for up to six months.

Results The number of patients with primary-outcome events was similar in the two groups (579 with fondaparinux [5.8 percent] vs. 573 with enoxaparin [5.7 percent]; hazard ratio in the fondaparinux group, 1.01; 95 percent confidence interval, 0.90 to 1.13), satisfying the noninferiority criteria. The number of events meeting this combined outcome showed a nonsignificant trend toward a lower value in the fondaparinux group at 30 days (805 vs. 864, P=0.13) and at the end of the study (1222 vs. 1308, P=0.06). The rate of major bleeding at nine days was markedly lower with fondaparinux than with enoxaparin (217 events [2.2 percent] vs. 412 events [4.1 percent]; hazard ratio, 0.52; P<0.001). The composite of the primary outcome and major bleeding at nine days favored fondaparinux (737 events [7.3 percent] vs. 905 events [9.0 percent]; hazard ratio, 0.81; P<0.001). Fondaparinux was associated with a significantly reduced number of deaths at 30 days (295 vs. 352, P=0.02) and at 180 days (574 vs. 638, P=0.05).

Conclusions Fondaparinux is similar to enoxaparin in reducing the risk of ischemic events at nine days, but it substantially reduces major bleeding and improves long term mortality and morbidity. (ClinicalTrials.gov number, NCT00139815 [ClinicalTrials.gov] .)

Source Information

The Writing Committee (Salim Yusuf, D.Phil., M.B., B.S., Shamir R. Mehta, M.D., Susan Chrolavicius, B.A., Rizwan Afzal, M.Sc., Janice Pogue, M.Sc., Christopher B. Granger, M.D., Andrzej Budaj, Ph.D., Ron J.G. Peters, M.D., Jean-Pierre Bassand, M.D., Lars Wallentin, Ph.D., Campbell Joyner, M.D., and Keith A.A. Fox, F.R.C.P.) assumes responsibility for the overall content and integrity of the article.

This article was published at www.nejm.org on March 14, 2006.

Address reprint requests to Dr. Yusuf at the Population Health Research Institute, McMaster Clinic, Hamilton General Hospital, 237 Barton St. East, Hamilton, ON L8L 2X2, Canada.

Full Text of this Article

Related Letters:

Fondaparinux versus Enoxaparin in Acute Coronary Syndromes
Majure D. T., Aberegg S. K., Yusuf S., Granger C. B., Mehta S. R.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:2829-2830, Jun 29, 2006. Correspondence

This article has been cited by other articles:

• Chase, A J, Fretz, E B, Warburton, W P, Klinke, W P, Carere, R G, Pi, D, Berry, B, Hilton, J D (2008). Association of the arterial access site at angioplasty with transfusion and mortality: the M.O.R.T.A.L study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg). Heart 94: 1019-1025 [Abstract] [Full Text]  
• Dobesh, P. P., Phillips, K. W., Haines, S. T. (2008). Optimizing antithrombotic therapy in patients with non-ST-segment elevation acute coronary syndrome. Am J Health Syst Pharm 65: S22-S28 [Abstract] [Full Text]  
• Coons, J. C, Battistone, S. (2008). 2007 Guideline Update for Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction: Focus on Antiplatelet and Anticoagulant Therapies. The Annals of Pharmacotherapy 42: 989-1001 [Abstract] [Full Text]  
• Schulman, S., Beyth, R. J., Kearon, C., Levine, M. N. (2008). Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 257S-298S [Abstract] [Full Text]  
• Harrington, R. A., Becker, R. C., Cannon, C. P., Gutterman, D., Lincoff, A. M., Popma, J. J., Steg, G., Guyatt, G. H., Goodman, S. G. (2008). Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 670S-707S [Abstract] [Full Text]  
• Goodman, S. G., Menon, V., Cannon, C. P., Steg, G., Ohman, E. M., Harrington, R. A. (2008). Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 708S-775S [Abstract] [Full Text]  
• Morrow, D. A. (2008). Antithrombotic Therapy to Support Primary PCI. NEJM 358: 2280-2282 [Full Text]  
• Crowther, M. A., Warkentin, T. E. (2008). Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 111: 4871-4879 [Abstract] [Full Text]  
• White, H. D., Chew, D. P., Hoekstra, J. W., Miller, C. D., Pollack, C. V. Jr, Feit, F., Lincoff, A. M., Bertrand, M., Pocock, S., Ware, J., Ohman, E. M., Mehran, R., Stone, G. W. (2008). Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.. J Am Coll Cardiol 51: 1734-1741 [Abstract] [Full Text]  
• Wang, T. Y., Chen, A. Y., Peterson, E. D., Becker, R. C., Gibler, W. B., Ohman, E. M., Roe, M. T. (2008). Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: observations from the CRUSADE quality improvement initiative. Eur Heart J 29: 1103-1109 [Abstract] [Full Text]  
• Bassand, J.-P. (2008). Bleeding and transfusion in acute coronary syndromes: a shift in the paradigm. Heart 94: 661-666 [Full Text]  
• Turpie, A. G.G. (2008). Selective factor Xa inhibition with fondaparinux: from concept to clinical benefit. Eur Heart J Suppl 10: C1-C7 [Abstract] [Full Text]  
• Eikelboom, J. W. (2008). Effect of fondaparinux 2.5 mg once daily on mortality: a meta-analysis of phase III randomized trials of venous thromboembolism prevention. Eur Heart J Suppl 10: C8-C13 [Abstract] [Full Text]  
• Bassand, J.-P. (2008). The place of fondaparinux in the ESC and ACC/AHA guidelines for anticoagulation in patients with non-ST elevation acute coronary syndromes. Eur Heart J Suppl 10: C22-C29 [Abstract] [Full Text]  
• Mehta, S. R. (2008). Clinical benefit and practical use of fondaparinux in the invasive management of patients with acute coronary syndromes. Eur Heart J Suppl 10: C14-C21 [Abstract] [Full Text]  
• Peters, R. J.G., Joyner, C., Bassand, J.-P., Afzal, R., Chrolavicius, S., Mehta, S. R., Oldgren, J., Wallentin, L., Budaj, A., Fox, K. A., Yusuf, S., for the OASIS-6 investigators, (2008). The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. Eur Heart J 29: 324-331 [Abstract] [Full Text]  
• Granger, C. B, Vogel, V., Cummings, S. R, Held, P., Fiedorek, F., Lawrence, M., Neal, B., Reidies, H., Santarelli, L., Schroyer, R., Stockbridge, N. L, Feng Zhao, (2008). Do we need to adjudicate major clinical events?. Clin Trials 5: 56-60 [Abstract]  
• Oldgren, J., Wallentin, L., Afzal, R., Bassand, J.-P., Budaj, A., Chrolavicius, S., Fox, K. A.A., Granger, C. B., Mehta, S. R., Pais, P., Peters, R. J.G., Xavier, D., Zhu, J., Yusuf, S., for the OASIS-6 Investigators, (2008). Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. Eur Heart J 29: 315-323 [Abstract] [Full Text]  
• American College of Cardiology/American Heart Asso, , Developed in Collaboration With the Canadian Cardi, , Endorsed by the American Academy of Family Physici, , 2007 Writing Group to Review New Evidence and Upda, , Antman, E. M., Hand, M., Armstrong, P. W., Bates, E. R., Green, L. A., Halasyamani, L. K., Hochman, J. S., Krumholz, H. M., Lamas, G. A., Mullany, C. J., Pearle, D. L., Sloan, M. A., Smith, S. C. JR (2008). 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. J Am Coll Cardiol 51: 210-247 [Full Text]  
• American College of Cardiology/American Heart Asso, , 2007 Writing Group to Review New Evidence and Upda, , King, S. B. III, Smith, S. C. Jr, Hirshfeld, J. W. Jr, Jacobs, A. K., Morrison, D. A., Williams, D. O. (2008). 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. J Am Coll Cardiol 51: 172-209 [Full Text]  
• Antman, E. M., Hand, M., Armstrong, P. W., Bates, E. R., Green, L. A., Halasyamani, L. K., Hochman, J. S., Krumholz, H. M., Lamas, G. A., Mullany, C. J., Pearle, D. L., Sloan, M. A., Smith, S. C. Jr, 2004 Writing Committee Members, , Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., Lamas, G. A., Mullany, C. J., Ornato, J. P., Pearle, D. L., Sloan, M. A., Smith, S. C. Jr, Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Buller, C. E., Creager, M. A., Ettinger, S. M., Halperin, J. L., Hunt, S. A., Krumholz, H. M., Kushner, F. G., Lytle, B. W., Nishimura, R., Page, R. L., Riegel, B., Tarkington, L. G., Yancy, C. W. (2008). 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the Canadian Cardiovascular Society Endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 117: 296-329 [Full Text]  
• King, S. B. III, Smith, S. C. Jr, Hirshfeld, J. W. Jr, Jacobs, A. K., Morrison, D. A., Williams, D. O., 2005 WRITING COMMITTEE MEMBERS, , Smith, S. C. Jr, Feldman, T. E., Hirshfeld, J. W. Jr, Jacobs, A. K., Kern, M. J., King, S. B. III, Morrison, D. A., O'Neill, W. W., Schaff, H. V., Whitlow, P. L., Williams, D. O., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Buller, C. E., Creager, M. A., Ettinger, S. M., Halperin, J. L., Hunt, S. A., Krumholz, H. M., Kushner, F. G., Lytle, B. W., Nishimura, R., Page, R. L., Riegel, B., Tarkington, L. G., Yancy, C. W. (2008). 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 117: 261-295 [Full Text]  
• Bassand, J.-P., Hamm, C. W. (2008). Non-ST-segment elevation acute coronary syndromes: an algorithm for decision: reply. Eur Heart J 29: 280-281 [Full Text]  
• Berger, P. B., Manoukian, S. V. (2007). Bleeding Is Bad.... Isn't It?. Circulation 116: 2776-2778 [Full Text]  
• Spencer, F. A., Moscucci, M., Granger, C. B., Gore, J. M., Goldberg, R. J., Steg, P. G., Goodman, S. G., Budaj, A., FitzGerald, G., Fox, K. A.A., for the GRACE Investigators, (2007). Does Comorbidity Account for the Excess Mortality in Patients With Major Bleeding in Acute Myocardial Infarction?. Circulation 116: 2793-2801 [Abstract] [Full Text]  
• Dumaine, R., Borentain, M., Bertel, O., Bode, C., Gallo, R., White, H. D., Collet, J.-P., Steinhubl, S. R., Montalescot, G. (2007). Intravenous Low-Molecular-Weight Heparins Compared With Unfractionated Heparin in Percutaneous Coronary Intervention: Quantitative Review of Randomized Trials. Arch Intern Med 167: 2423-2430 [Abstract] [Full Text]  
• Bhatt, D. L. (2007). Intensifying Platelet Inhibition -- Navigating between Scylla and Charybdis. NEJM 357: 2078-2081 [Full Text]  
• Mehta, S. R., Granger, C. B., Eikelboom, J. W., Bassand, J.-P., Wallentin, L., Faxon, D. P., Peters, R. J.G., Budaj, A., Afzal, R., Chrolavicius, S., Fox, K. A.A., Yusuf, S. (2007). Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Results From the OASIS-5 Trial. J Am Coll Cardiol 50: 1742-1751 [Abstract] [Full Text]  
• Lobo, B. L. (2007). Use of newer anticoagulants in patients with chronic kidney disease. Am J Health Syst Pharm 64: 2017-2026 [Abstract] [Full Text]  
• Fox, K. A.A., Bassand, J.-P., Mehta, S. R., Wallentin, L., Theroux, P., Piegas, L. S., Valentin, V., Moccetti, T., Chrolavicius, S., Afzal, R., Yusuf, S., on behalf of the OASIS 5 Investigators, (2007). Influence of Renal Function on the Efficacy and Safety of Fondaparinux Relative to Enoxaparin in Non ST-Segment Elevation Acute Coronary Syndromes. ANN INTERN MED 147: 304-310 [Abstract] [Full Text]  
• Murphy, S. A., Gibson, C. M., Morrow, D. A., Van de Werf, F., Menown, I. B., Goodman, S. G., Mahaffey, K. W., Cohen, M., McCabe, C. H., Antman, E. M., Braunwald, E. (2007). Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J 28: 2077-2086 [Abstract] [Full Text]  
• Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E. Jr, Chavey, W. E. II, Fesmire, F. M., Hochman, J. S., Levin, T. N., Lincoff, A. M., Peterson, E. D., Theroux, P., Wenger, N. K., Wright, R. S., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Krumholz, H. M., Kushner, F. G., Lytle, B. W., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2007). ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50: e1-e157 [Full Text]  
• Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E. Jr, Chavey, W. E. II, Fesmire, F. M., Hochman, J. S., Levin, T. N., Lincoff, A. M., Peterson, E. D., Theroux, P., Wenger, N. K., Wright, R. S., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Krumholz, H. M., Kushner, F. G., Lytle, B. W., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2007). ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50: 652-726 [Full Text]  
• Hirsh, J., O'Donnell, M., Eikelboom, J. W. (2007). Beyond Unfractionated Heparin and Warfarin: Current and Future Advances. Circulation 116: 552-560 [Full Text]  
• LaPointe, N. M. A., Chen, A. Y., Alexander, K. P., Roe, M. T., Pollack, C. V. Jr, Lytle, B. L., Ohman, M. E., Gibler, B. W., Peterson, E. D. (2007). Enoxaparin Dosing and Associated Risk of In-Hospital Bleeding and Death in Patients With Non ST-Segment Elevation Acute Coronary Syndromes. Arch Intern Med 167: 1539-1544 [Abstract] [Full Text]  
• Dixon, S. R., Grines, C. L., O'Neill, W. W. (2007). The Year in Interventional Cardiology. J Am Coll Cardiol 50: 270-285 [Full Text]  
• Eikelboom, J. W., Weitz, J. I. (2007). A Replacement for Warfarin: The Search Continues. Circulation 116: 131-133 [Full Text]  
• Authors/Task Force Members, , Bassand, J.-P., Hamm, C. W., Ardissino, D., Boersma, E., Budaj, A., Fernandez-Aviles, F., Fox, K. A.A., Hasdai, D., Ohman, E. M., Wallentin, L., Wijns, W., ESC Committee for Practice Guidelines (CPG), , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Kristensen, S. D., Widimsky, P., McGregor, K., Sechtem, U., Tendera, M., Hellemans, I., Gomez, J. L. Z., Silber, S., Funck-Brentano, C., Document Reviewers, , Kristensen, S. D., Andreotti, F., Benzer, W., Bertrand, M., Betriu, A., De Caterina, R., DeSutter, J., Falk, V., Ortiz, A. F., Gitt, A., Hasin, Y., Huber, K., Kornowski, R., Lopez-Sendon, J., Morais, J., Nordrehaug, J. E., Silber, S., Steg, P. G., Thygesen, K., Tubaro, M., Turpie, A. G.G., Verheugt, F., Windecker, S. (2007). Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 28: 1598-1660 [Full Text]  
• Giugliano, R. P., Wiviott, S. D., Stone, P. H., Simon, D. I., Schweiger, M. J., Bouchard, A., Leesar, M. A., Goulder, M. A., Deitcher, S. R., McCabe, C. H., Braunwald, E., for the ANTHEM-TIMI-32 Investigators, (2007). Recombinant Nematode Anticoagulant Protein c2 in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: The ANTHEM-TIMI-32 Trial. J Am Coll Cardiol 49: 2398-2407 [Abstract] [Full Text]  
• Peters, R. J G, Mehta, S., Yusuf, S. (2007). Acute coronary syndromes without ST segment elevation. BMJ 334: 1265-1269 [Full Text]  
• Bassand, J.-P. (2007). Impact of anaemia, bleeding, and transfusions in acute coronary syndromes: a shift in the paradigm. Eur Heart J 28: 1273-1274 [Full Text]  
• Spinler, S. A. (2007). Managing acute coronary syndrome: Evidence-based approaches. Am J Health Syst Pharm 64: S14-S24 [Abstract] [Full Text]  
• Alexander, K. P., Newby, L. K., Cannon, C. P., Armstrong, P. W., Gibler, W. B., Rich, M. W., Van de Werf, F., White, H. D., Weaver, W. D., Naylor, M. D., Gore, J. M., Krumholz, H. M., Ohman, E. M. (2007). Acute Coronary Care in the Elderly, Part I: Non-ST-Segment-Elevation Acute Coronary Syndromes: A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology: In Collaboration With the Society of Geriatric Cardiology. Circulation 115: 2549-2569 [Abstract] [Full Text]  
• Rao, S. V., Eikelboom, J. A., Granger, C. B., Harrington, R. A., Califf, R. M., Bassand, J.-P. (2007). Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 28: 1193-1204 [Abstract] [Full Text]  
• De Caterina, R., Husted, S., Wallentin, L., Agnelli, G., Bachmann, F., Baigent, C., Jespersen, J., Kristensen, S. D., Montalescot, G., Siegbahn, A., Verheugt, F. W.A., Weitz, J. (2007). Anticoagulants in heart disease: current status and perspectives. Eur Heart J 0: ehl492v1-34 [Full Text]  
• Stone, G. W., Bertrand, M. E., Moses, J. W., Ohman, E. M., Lincoff, A. M., Ware, J. H., Pocock, S. J., McLaurin, B. T., Cox, D. A., Jafar, M. Z., Chandna, H., Hartmann, F., Leisch, F., Strasser, R. H., Desaga, M., Stuckey, T. D., Zelman, R. B., Lieber, I. H., Cohen, D. J., Mehran, R., White, H. D., for the ACUITY Investigators, (2007). Routine Upstream Initiation vs Deferred Selective Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes: The ACUITY Timing Trial. JAMA 297: 591-602 [Abstract] [Full Text]  
• Mahaffey, K. W., Harrington, R. A. (2007). Optimal Timing for Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes: Questions, Answers, and More Questions. JAMA 297: 636-639 [Full Text]  
• Collet, J.-P., Dumaine, R., Montalescot, G. (2007). Antithrombin treatment in patients with non-ST-elevation acute coronary syndromes undergoing percutaneous coronary intervention. Eur Heart J Suppl 9: A11-A24 [Abstract] [Full Text]  
• Bindra, K., Berry, C., Rogers, J., Stewart, N., Watts, M., Christie, J., Cobbe, S.M., Eteiba, H. (2006). Abnormal haemoglobin levels in acute coronary syndromes.. QJM 99: 851-862 [Abstract] [Full Text]  
• Mahaffey, K. W., Becker, R. C. (2006). The Scientific Community's Quest to Identify Optimal Targets for Anticoagulant Pharmacotherapy. Circulation 114: 2313-2316 [Full Text]  
• Stone, G. W., McLaurin, B. T., Cox, D. A., Bertrand, M. E., Lincoff, A. M., Moses, J. W., White, H. D., Pocock, S. J., Ware, J. H., Feit, F., Colombo, A., Aylward, P. E., Cequier, A. R., Darius, H., Desmet, W., Ebrahimi, R., Hamon, M., Rasmussen, L. H., Rupprecht, H.-J., Hoekstra, J., Mehran, R., Ohman, E. M., the ACUITY Investigators, (2006). Bivalirudin for Patients with Acute Coronary Syndromes.. NEJM 355: 2203-2216 [Abstract] [Full Text]  
• Yusuf, S., Mehta, S. R. (2006). Fondaparinux in Patients With ST-Segment Elevation Myocardial Infarction--Reply. JAMA 296: 2088-2089 [Full Text]  
• (2006). Additional articles abstracted in ACP Journal Club. Evid. Based Med. 11: 158-158 [Full Text]  
• Giugliano, R. P., Braunwald, E. (2006). The Year in Non-ST-Segment Elevation Acute Coronary Syndromes. J Am Coll Cardiol 48: 386-395 [Full Text]  
• Majure, D. T., Aberegg, S. K., Yusuf, S., Granger, C. B., Mehta, S. R. (2006). Fondaparinux versus enoxaparin in acute coronary syndromes.. NEJM 354: 2829-2829 [Full Text]  
• DeCarolis, D. D., Sleight, P., Eikelboom, J. W., Bassand, J.-P., Antman, E. M., Braunwald, E. (2006). Enoxaparin versus unfractionated heparin in ST-elevation myocardial infarction.. NEJM 354: 2830-2831 [Full Text]  
• Malik, I. (2006). JournalScan. Heart 92: 862-864 [Full Text]  
• (2006). Anticoagulants in Acute Coronary Syndromes: More Progress. JWatch Emergency Med. 2006: 3-3 [Full Text]  
• (2006). Fondaparinux for Acute Coronary Syndromes. JWatch General 2006: 3-3 [Full Text]  
• (2006). Fondaparinux: Benefits in STEMI and NSTEMI. Journal Watch Cardiology 2006: 1-1 [Full Text]  
• Gibbons, R. J., Fuster, V. (2006). Therapy for Patients with Acute Coronary Syndromes -- New Opportunities. NEJM 354: 1524-1527 [Full Text]  
• Warkentin, T. E. (2006). Think of HIT. ASH Education Book 2006: 408-414 [Abstract] [Full Text]  
• Bauer, K. A. (2006). New Anticoagulants. ASH Education Book 2006: 450-456 [Abstract] [Full Text]